🇺🇸 FDA
Patent

US 12247201

Materials and methods for treatment of autosomal dominant retinitis pigmentosa

granted A61KA61K31/7088A61K38/465

Quick answer

US patent 12247201 (Materials and methods for treatment of autosomal dominant retinitis pigmentosa) held by CRISPR THERAPEUTICS AG expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/7088, A61K38/465, A61P, A61P27/02